Sleep optimization protocols
Sleep optimization protocols include CBT-I, the first-line evidence-based clinical treatment for insomnia, and a growing range of device-based interventions targeting circadian alignment, body temperature regulation, and closed-loop neurostimulation. The underlying physiology, circadian rhythms, homeostatic sleep drive, and sleep architecture, is well-characterized. The longevity case for sleep quality is substantiated by research linking chronic deprivation to cardiovascular, metabolic, and neurodegenerative risk. The Atlas currently reflects device companies (Somnee, Arcascope, Moona) rather than clinical CBT-I providers. Evidence tier: well-evidenced.
What it is
Sleep optimization protocols encompass both clinical interventions for sleep disorders and structured approaches for improving sleep quality and architecture in otherwise healthy adults seeking performance and longevity benefits. The field rests on well-established sleep physiology: the circadian rhythm, a 24-hour biological clock governed primarily by light exposure, regulates the timing of sleep; the homeostatic sleep drive, also called sleep pressure, builds during wakefulness and dissipates during sleep; and sleep itself proceeds in 90-minute cycles alternating between light sleep, slow-wave (deep) sleep, and REM sleep, each serving distinct restorative and memory-consolidation functions. Research synthesized by Matthew Walker at UC Berkeley, most accessibly in his 2017 book Why We Sleep, has anchored the public and industry understanding of sleep as a longevity variable, linking chronic sleep deprivation to elevated risk of cardiovascular disease, metabolic dysfunction, neurodegeneration, and immune suppression. The first-line clinical treatment for chronic insomnia is Cognitive Behavioral Therapy for Insomnia (CBT-I), endorsed by the American Academy of Sleep Medicine and the American College of Physicians over pharmacological approaches for long-term management. In the commercial longevity economy, the modality is primarily represented by device and wearable companies targeting circadian alignment, thermal regulation, and closed-loop neurological sleep enhancement.
Who it is for
Adults experiencing chronic insomnia benefit from CBT-I and related clinical sleep interventions, where the evidence base is robust. High-performing and longevity-focused individuals without diagnosed sleep disorders represent the larger commercial market, seeking to optimize sleep architecture, circadian alignment, and recovery quality. The modality is relevant across the entire adult lifespan, with sleep quality declining measurably with age and poor sleep increasingly recognized as an upstream driver of multiple aging-related conditions.
What to expect
Clinical sleep optimization typically begins with a structured intake assessing sleep history, chronotype, sleep hygiene behaviors, and daytime impairment. CBT-I is delivered in 6 to 8 weekly sessions, in-person or via app-based programs, addressing sleep restriction, stimulus control, cognitive restructuring, and relaxation techniques. Device-based sleep optimization, the segment represented in the Atlas, operates differently: Somnee delivers EEG-based closed-loop neurostimulation during pre-sleep, targeting brain state for faster sleep onset; Moona uses a thermal pillow pad to modulate core body temperature in alignment with the physiological cooling required for sleep onset; and Arcascope provides a circadian rhythm modeling platform using wearable data to optimize sleep and activity timing. These devices are consumer and semi-clinical products, not FDA-cleared medical treatments for insomnia. The Atlas currently reflects the device segment of this modality rather than clinical CBT-I providers.
History and background
Sleep medicine emerged as a formal clinical specialty in the 1970s with the establishment of sleep laboratories and the characterization of obstructive sleep apnea and other sleep disorders. CBT-I was developed through the 1980s and 1990s, with Charles Morin and others publishing landmark trials demonstrating its superiority to pharmacological approaches in long-term outcomes. The modality's entry into mainstream longevity discourse accelerated sharply after Matthew Walker's Why We Sleep (2017), which brought a synthesis of sleep deprivation research to a large public audience and positioned sleep duration and quality as foundational longevity variables. Somnee was co-founded by Walker, directly connecting the research narrative to a commercial device. The commercial wearable and device sector for sleep optimization has grown substantially since 2015, tracking the broader expansion of consumer health hardware.
Worth knowing
CBT-I produces more durable improvements in insomnia than sleep medications in head-to-head trials and carries no dependency risk, yet it remains underutilized in primary care relative to pharmacological prescribing, largely due to access barriers and clinician training gaps. Core body temperature must drop by approximately 1 to 2 degrees Fahrenheit for sleep onset to occur, which is why the thermal manipulation approach used by devices like Moona has a physiological basis rather than being a purely behavioral intervention. Matthew Walker co-founding Somnee is a notable instance of an academic researcher moving directly into commercialization of their own research domain, a pattern increasingly common in longevity science.
Offered across the Atlas 3
Related modalities